Form 4: Relay Therapeutics Executive Sells Shares to Cover Tax Obligations

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 986 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Summary

• On March 27, 2025, Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 986 shares of Relay Therapeutics common stock.
• The sale was executed at a price of $2.84 per share.
• The transaction was conducted to cover income tax withholding obligations related to the vesting of 2,188 restricted stock units (RSUs) on March 26, 2025.
• Following the transaction, Bergstrom beneficially owns 615,052 shares of Relay Therapeutics common stock, including 374,731 shares underlying RSUs.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. This particular filing reflects a common practice of executives selling shares to cover tax obligations arising from the vesting of equity awards.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• Upon vesting, these RSUs are considered income and are subject to income tax.
• To cover these tax obligations, executives often sell a portion of the shares received upon vesting.
• This practice is common across various industries and is not unique to Relay Therapeutics.
• Comparable companies in the biotechnology sector, such as Amgen, Gilead Sciences, and Biogen, also see similar transactions by their executives.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholders, but it is generally considered a routine transaction.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Relay Therapeutics, RLAY, Donald A. Bergstrom, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Obligations, Beneficial Ownership